Cargando…

Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study

The purposes of this study were to re‐confirm the usefulness of PET/CT in the differentiation of benignity/malignancy of neurogenic tumors in NF1 patients, and to analyze the natural course of plexiform neurofibroma (pNF) and clarify whether PET/CT is also useful for detecting tumors other than neur...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishida, Yoshihiro, Ikuta, Kunihiro, Ito, Shinji, Urakawa, Hiroshi, Sakai, Tomohisa, Koike, Hiroshi, Ito, Kan, Imagama, Shiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935790/
https://www.ncbi.nlm.nih.gov/pubmed/33415792
http://dx.doi.org/10.1111/cas.14802
_version_ 1783661068614107136
author Nishida, Yoshihiro
Ikuta, Kunihiro
Ito, Shinji
Urakawa, Hiroshi
Sakai, Tomohisa
Koike, Hiroshi
Ito, Kan
Imagama, Shiro
author_facet Nishida, Yoshihiro
Ikuta, Kunihiro
Ito, Shinji
Urakawa, Hiroshi
Sakai, Tomohisa
Koike, Hiroshi
Ito, Kan
Imagama, Shiro
author_sort Nishida, Yoshihiro
collection PubMed
description The purposes of this study were to re‐confirm the usefulness of PET/CT in the differentiation of benignity/malignancy of neurogenic tumors in NF1 patients, and to analyze the natural course of plexiform neurofibroma (pNF) and clarify whether PET/CT is also useful for detecting tumors other than neurogenic tumors. PET/CT was prospectively imaged in 36 NF1 patients. There were 14 malignant peripheral nerve sheath tumors (MPNSTs) in 14 patients, and 54 pNFs in 30 patients. Nine patients had both MPNST and pNF. Maximal standardized uptake value (SUVmax) was significantly higher in MPNST (median 7.6: range 4.1‐10.4) (P < .001) compared with that of pNF (median 3.7: range 1.6‐9.3). The cut‐off value of 5.8 resulted in a sensitivity of 78.6% and specificity of 88.9%. Median age was 29 y, and median maximum tumor diameter was 82 mm in 14 MPNST patients. The 5‐y overall survival rate was 46.8%. Three patients with low‐grade MPNST were alive without disease at the time of this report. In 9 patients in which pNF and MPNST co‐existed, 2 showed a higher SUVmax of pNF than that of MPNST. Natural history analysis of pNF (n = 43) revealed that no factors significantly correlated with increased tumor size. Nine lesions other than neurogenic tumors were detected by PET/CT including 5 thyroid lesions and 3 malignant neoplasms. This study revealed the usefulness and limitation of PET/CT for NF1 patients. In the future, it will be necessary to study how to detect over time the malignant transformation of pNF to MPNST, via an intermediate tumor.
format Online
Article
Text
id pubmed-7935790
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-79357902021-03-15 Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study Nishida, Yoshihiro Ikuta, Kunihiro Ito, Shinji Urakawa, Hiroshi Sakai, Tomohisa Koike, Hiroshi Ito, Kan Imagama, Shiro Cancer Sci Original Articles The purposes of this study were to re‐confirm the usefulness of PET/CT in the differentiation of benignity/malignancy of neurogenic tumors in NF1 patients, and to analyze the natural course of plexiform neurofibroma (pNF) and clarify whether PET/CT is also useful for detecting tumors other than neurogenic tumors. PET/CT was prospectively imaged in 36 NF1 patients. There were 14 malignant peripheral nerve sheath tumors (MPNSTs) in 14 patients, and 54 pNFs in 30 patients. Nine patients had both MPNST and pNF. Maximal standardized uptake value (SUVmax) was significantly higher in MPNST (median 7.6: range 4.1‐10.4) (P < .001) compared with that of pNF (median 3.7: range 1.6‐9.3). The cut‐off value of 5.8 resulted in a sensitivity of 78.6% and specificity of 88.9%. Median age was 29 y, and median maximum tumor diameter was 82 mm in 14 MPNST patients. The 5‐y overall survival rate was 46.8%. Three patients with low‐grade MPNST were alive without disease at the time of this report. In 9 patients in which pNF and MPNST co‐existed, 2 showed a higher SUVmax of pNF than that of MPNST. Natural history analysis of pNF (n = 43) revealed that no factors significantly correlated with increased tumor size. Nine lesions other than neurogenic tumors were detected by PET/CT including 5 thyroid lesions and 3 malignant neoplasms. This study revealed the usefulness and limitation of PET/CT for NF1 patients. In the future, it will be necessary to study how to detect over time the malignant transformation of pNF to MPNST, via an intermediate tumor. John Wiley and Sons Inc. 2021-01-22 2021-03 /pmc/articles/PMC7935790/ /pubmed/33415792 http://dx.doi.org/10.1111/cas.14802 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nishida, Yoshihiro
Ikuta, Kunihiro
Ito, Shinji
Urakawa, Hiroshi
Sakai, Tomohisa
Koike, Hiroshi
Ito, Kan
Imagama, Shiro
Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title_full Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title_fullStr Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title_full_unstemmed Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title_short Limitations and benefits of FDG‐PET/CT in NF1 patients with nerve sheath tumors: A cross‐sectional/longitudinal study
title_sort limitations and benefits of fdg‐pet/ct in nf1 patients with nerve sheath tumors: a cross‐sectional/longitudinal study
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935790/
https://www.ncbi.nlm.nih.gov/pubmed/33415792
http://dx.doi.org/10.1111/cas.14802
work_keys_str_mv AT nishidayoshihiro limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT ikutakunihiro limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT itoshinji limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT urakawahiroshi limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT sakaitomohisa limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT koikehiroshi limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT itokan limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy
AT imagamashiro limitationsandbenefitsoffdgpetctinnf1patientswithnervesheathtumorsacrosssectionallongitudinalstudy